Cargando…
Thyroid Cancer Imaging In Vivo by Targeting the Anti-Apoptotic Molecule Galectin-3
BACKGROUND: The prevalence of thyroid nodules increases with age, average 4–7% for the U.S.A. adult population, but it is much higher (19–67%) when sub-clinical nodules are considered. About 90% of these lesions are benign and a reliable approach to their preoperative characterization is necessary....
Autores principales: | Bartolazzi, Armando, D'Alessandria, Calogero, Parisella, Maria Gemma, Signore, Alberto, Del Prete, Fabrizio, Lavra, Luca, Braesch-Andersen, Sten, Massari, Roberto, Trotta, Carlo, Soluri, Alessandro, Sciacchitano, Salvatore, Scopinaro, Francesco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582451/ https://www.ncbi.nlm.nih.gov/pubmed/19020658 http://dx.doi.org/10.1371/journal.pone.0003768 |
Ejemplares similares
-
Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives
por: Bartolazzi, Armando, et al.
Publicado: (2018) -
Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo
por: Peplau, Emanuel, et al.
Publicado: (2021) -
The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas
por: Lavra, Luca, et al.
Publicado: (2011) -
Transparency in Negotiation of European Union With Big Pharma on COVID-19 Vaccines
por: Sciacchitano, Salvatore, et al.
Publicado: (2021) -
Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using ((89)Zr)-DFO- Galectin3-F(ab')(2) mAb
por: Varasteh, Zohreh, et al.
Publicado: (2021)